Giant cell arteritis

Area of Science:

• Rheumatology
• Internal Medicine
• Vascular Inflammation

Background:

• Giant cell arteritis (GCA) incidence has risen significantly in elderly populations over the past 50 years.
• GCA is now a major contributor to morbidity in older individuals.
• The underlying causes and pathogenesis of GCA are not well understood.

Purpose of the Study:

• To summarize the current understanding of Giant Cell Arteritis.
• To highlight the established treatment protocols for GCA.
• To clarify the role of different anti-inflammatory drug classes in managing GCA.

Main Methods:

• Literature review of GCA epidemiology and treatment.
• Analysis of clinical guidelines for GCA management.
• Evaluation of the efficacy of anti-inflammatory drugs in GCA.

Main Results:

• Giant cell arteritis is a growing concern for elderly health.
• Glucocorticosteroids are the established first-line therapy for all forms of GCA.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) have demonstrated no benefit for vascular complications in GCA.

Conclusions:

• Giant cell arteritis requires continued research into its etiology and pathogenesis.
• Glucocorticosteroids remain the cornerstone of GCA treatment.
• NSAIDs should not be relied upon for managing GCA or its vascular sequelae.